Advances in Myositis and Lingering Unmet Needs Ahead of MDA 2023
Angela Lek, PhD, and Tahseen Mozaffar, MD, offered their insight into myositis and the clinical needs for the population, ahead of a focused session on it, chaired by Mozzafar at the MDA’s Clinical & Scientific Conference.
Rare, Fatal Case of Neuromyelitis Optica Post–COVID-19 Vaccination Explained
A rare case of neuromyelitis optica was reported with a woman aged in her 70s from Iran who experienced neurological symptoms after COVID-19 vaccination.
Detecting Cognitive Decline in Underserved Communities Using 5-Cog: Joe Verghese, MBBS, MS
The director of the Montefiore Einstein Center for the Aging Brain provided insight on how the 5-Cog assessment tool is specifically tailored for people from a range of racial and ethnic background, education levels, and socioeconomic circumstances. [WATCH TIME: 4 minutes]
NeuroDerm’s 24-Hour Subcutaneous Levodopa Infusion Meets Primary End Point in Phase 3 BouNDless Study
In addition to improving ON time in patients with Parkinson disease, ND0612 was well tolerated, with only 6.3% of patients randomized to the treatment discontinuing the trial.
Difference Between Health Equity and Health Disparities in Epilepsy: Elizabeth Felton, MD, PhD
The assistant professor in the Department of Neurology at the University of Wisconsin spoke about the differences between health disparities and health equity in epilepsy care at the 2022 AES Conference. [WATCH TIME: 3 minutes]
Adolescents and Parents Prefer Receiving Medical Information at Diagnosis of Narcolepsy
A questionnaire showed that adolescents with narcolepsy and parents prefer to receive details on narcolepsy at the time of diagnosis from a healthcare provider.
CSF Glucocerebrosidase Activity Associated With Risk of Dementia in Parkinson Disease
A population-based incident of Parkinson disease cases showed patients were more likely to develop PD dementia in 10 years with a lower level of lysosomal enzyme glucocerebrosidase activity.
Special Episode: Lecanemab Approved for Alzheimer Disease
Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Sharon Cohen, MD, FRCPC. [LISTEN TIME: 14 minutes]
Significance of Expanding Antiamyloid Therapy Class, Toolbox to Treat Alzheimer: Sharon Cohen, MD, FRCPC
The behavioral neurologist and medical director of the Toronto Memory Program provided perspective on how lecanemab’s FDA approval changes the capabilities of treating Alzheimer disease in its earliest stages. [WATCH TIME: 3 minutes]
Eisai Files Supplemental BLA for Traditional Approval of Lecanemab
Approved under the accelerated approval pathway, the current indication for lecanemab states the company must provide phase 4 study evidence to confirm the agent’s effect in Alzheimer disease.
Debating Surgery in Genetic Disorders with Epilepsy: Scott Perry, MD
The head of neurosciences at the Jane and John Justin Neurosciences Center of Cook Children’s Medical Center spoke about his experience in a debate on surgery in genetic disorders at the 2022 AES Conference. [WATCH TIME: 3 minutes]
This Week on NeurologyLive® — January 9, 2023
Here's some of what is coming soon to NeurologyLive® this week.
The Definition of a Seizure, Clinical Controversies: Michael Sperling, MD
The Baldwin Keyes professor of neurology at Thomas Jefferson University, spoke with us at the 2022 AES Conference about the definition of a seizure. [WATCH TIME: 3 minutes]
NeurologyLive® Brain Games: January 8, 2023
Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is Alzheimer disease and dementia.
Rare Seronegative NMOSD Case Identified
A study reported a rare case of seronegative NMOSD with a middle-aged man in Nepal who did not improve in clinical status and performance after given treatment.
ARISE Results Highlight Dimethyl Fumarate’s Impact as Disease-Modifying Therapy for RIS
For the first time ever, investigators identified a treatment benefit that extends the time to clinical conversion in RIS and reduces new or newly-enlarging T-weighted hyperintense lesions.
Acupuncture Shows Effectiveness for Anxiety in Patients With Parkinson Disease
After 2 months of treatment, findings showed more improvement in anxiety and mental status with acupuncture in patients with Parkinson Disease than those on sham acupuncture.
Pimavanserin's Positive Impact on Mortality, Concerns Raised Over Lecanemab Patient Death, FDA Clears Zoom RDL Access System
Neurology News Network for the week ending January 7, 2022. [WATCH TIME: 4 minutes]
NeurologyLive® Friday 5 — January 6, 2023
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending January 6, 2023.
FDA Approves Eisai’s Lecanemab for the Treatment for Alzheimer Disease
Marketed as Leqembi, the agent was approved through the accelerated approval pathway and was based on a major study featuring almost 900 patients with early Alzheimer disease.
FDA Designates Myasthenia Gravis Agent Rozanolixizumab Application for Priority Review
UCB’s rozanolixizumab received priority review on its biologic license application by FDA and expects feedback during the second quarter of 2023.
Results from the Subgroup Analysis of BECOME Caregiver Survey: Robert Iannone, MD, MSCE
The executive vice president of Global Head of Research and Development at Jazz Pharmaceuticals, spoke on the results from the BECOME study presented at the 2022 AES Conference. [WATCH TIME: 6 minutes]
Pimavanserin Lowers Mortality Better in Parkinson Disease Than Other Atypical Antipsychotics
Findings from a large-scale trial of adults aged 65 and older with Parkinson disease showed that treatment with pimavanserin was associated with lower risk of mortality than other atypical antipsychotics.
LX9211’s Impact on Sleep Interference and Neuropathic Pain
Anand Patel, MD, CPI, chief medical officer at Conquest Research, spoke about the findings from the phase 2 RELIEF-DPN-1 trial assessing LX9211 in sleep health.
Clinicians Raise Concerns Over Lecanemab Following Patient Death Treated With tPA for Stroke
In the phase 3 Clarity AD trial, a 65-year-old patient treated with lecanemab died because of multiple cerebral hemorrhages after undergoing tissue plasminogen activator therapy for ischemic stroke.
Case Report Highlights Diagnosis of Antibody-Positive NMOSD After Second COVID-19 Vaccination
A rare case report illustrated an 80-year-old man with aquaporin-4 antibody-positive NMOSD following a second dose of the Pfizer-BioNTech COVID-19 mRNA BNT162b2 vaccine.
Rare Epilepsies, Comorbidities, and Genetic Therapies: Danielle Andrade, MD, MSc, FRCPC
The professor of neurology at the University of Toronto talked about 3 conditions that were discussed during the epilepsy therapies symposium at the 2022 AES Conference. [WATCH TIME: 5 minutes]
Timing of Orthostatic Hypotension, Not Symptom Severity, Increases Dementia Risk in Parkinson Disease, Multiple System Atrophy
The increased risk of dementia in patients showing early orthostatic hypotension was independent of the presence of concomitant supine hypertension and other factors associated with cognitive impairment.
FDA Clears First Stroke-Specific Radial Access Platform for Mechanical Thrombectomy
With this new approval, the Zoom RDL becomes the newest addition to Imperative’s Zoom Stroke Solution, a complete stroke system designed for effective clot removal in ischemic stroke.
Creating Innovative Ways to Improve Alzheimer Disease Prevention: Miia Kivipelto, MD, PhD
The professor of clinical geriatric epidemiology at Karolinska Institutet discussed strategies for lowering the risk of Alzheimer disease, and the new ways to approach prevention. [WATCH TIME: 4 minutes]
2 Clarke Drive Cranbury, NJ 08512